Tumor cell contamination of bone marrow harvest products: Clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy

Journal of Hematotherapy and Stem Cell Research

Volumn 5, Issue 6, 1996, Pages 617-624

  Brockstein, Bruce E ^a   Ross, Amy A ^b   Moss, Thomas J ^c   Kahn, Douglas G ^d   Hollingsworth, Kristi ^a   Williams, Stephanie F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Cell Pro Inc   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d BIS Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER TRANSPLANTATION; CLINICAL ARTICLE; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

EID: 0030448245     PISSN: 15258165     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.1.1996.5.617     Document Type: Article

References (28)

1. Antman, K.S., Armitage, J.O., Horowitz, M.M., et al. Autotransplants for breast cancer in North America. Proc. ASCO 67 (abstract 69), 13:1994.
2. Ross, A.A., Cooper, B.W., Lazarus, H.M., et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunohistochemical and clonogenic assay techniques. Blood 82:2605, 1993.
3. Moss, T.J., Sanders, D.G., Lasky, L.C., et al. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 76:1879, 1990.
4. Shpall, E.J., Jones, R.B., Bearman, S.I., et al. Transplantation of enriched CC34-positive autologous marrow into breast cancer patients following high dose chemotherapy: Influence of CD34-positive peripheral blood progenitors and growth factors on engraftment. J. Clin. Oncol. 12:28, 1994.
5. Sharp, J.G., Joshi, S.S., Armitage, J.O., et al. Significance of detection of occult non-Hodgkin's lymphoma in histologically uninvolved bone marrow by culture technique. Blood 79:1074, 1992.
6. Gribben, J.G., Freedman, A.S., Woo, S.D., et al. All advanced stage non-Hodgkin's lymphoma patients with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275, 1991.
7. Passos-Coelho, J., Ross, A.A., Davis, J.M., et al. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: Effect of ex vivo purging with 4-hydroxycyclophosphamide. Cancer Rep. 54:2366, 1994.
8. Brugger, W., Bross, K., Glatt, M., et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83:636, 1994.
9. Moss, T., Cairo, M., Santana, V., et al. Clonogenicity of circulating neuroblastoma cells: Implications regarding peripheral blood stem cell transplantation. Blood 83:3085, 1994.
10. Gribben, J.G., Freedman, A.S., Neuberg, D., et al. Immunologie purging of marrow assessed by pcr before autologous bone marrow transplantation for B-cell lymphoma. N. Engl. J. Med. 325:1525, 1991.
11. Brenner, M.K., Rill, D:R., Moen, R.C., et al. Gene-marking to trace the origin of relapse after bone marrow transplantation. Lancet 341:85, 1993.
12. Rill, D.R., Santana, V.M., Roberts, M., et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84:380, 1994.
13. Gulati, S.C., Romero, C.E. & Ciavarella, D. Is bone marrow purging proving to be of value? Oncology 8:19, 1994.
14. Gorin, N.C., Aegerter, P., Auvert, B., et al. Autologous bone marrow transplantation for acute myelogenous leukemia in first remission: A European survey of the role of bone marrow purging. Blood 75:1606, 1990.
15. Grad, G., Lane, N., Zimmerman, T., et al. High-dose chemotherapy (HDC) and autologous stem cell support in metastatic breast cancer: The University of Chicago experience. Proc. ASCO 1994: 13:73 (abstract no. 94).
16. Myers, S.E., & Williams, S.F. Role of high-dose chemotherapy and autologous stem cell support in treatment of breast cancer. Hematol. Oncol. Clin. North Am. 7:631, 1993.
17. Gribben, J.G. & Nadler, L.M. Purging of autologous bone marrow in the treatment of non-Hodgkin's lymphoma. Important Adv. Oncol. 139, 1993.
18. Osborne, M.P. & Rosen, P.P. Detection and management of bone marrow micrometastases in breast cancer. Oncology 8:25, 1994.
19. Mansi, J.L., Easton, D., Berger, U., et al. Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years follow-up. Eur. J. Cancer 27:1552, 1991.
20. Diel, I.J., Kaufmann, M., Goerner, R., et al. Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastases. J. Clin. Oncol. 10:1534, 1992.
21. Harbeck, N., Untch, M., Patche, L., et al. Tumor cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a three year median follow-up. Br. J. Cancer 69:566, 1994.
22. Cote, R.J., Rosen, P.P., Lesser, M.L., et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J. Clin. Oncol. 9:1749, 1991.
23. Dearnaley, D.P., Ormerod, M.G. & Sloane, J. Micrometastases in breast cancer: Long-term follow-up in the first patient cohort. Eur. J. Cancer 27:236, 1991.
24. Kamby, C., Rasmussen, B.B. & Kristensen, B. Prognostic indicators of metastatic bone disease in human breast cancer. Cancer 68:2045, 1991.
25. Salvadori, B., Squicciarini, P., Rovini, D., et al. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients. Eur. J. Cancer 26:865, 1990.
26. O'Briant, K.C., Shpall, E.J., Houston, L.L., et al. Elimination of clonogenic breast cancer cells from human bone marrow. Cancer 68:1272, 1991.
27. Negrin, R.S. Pesandro, J. Detection of tumor cells in purged bone marrow and peripheral-blood mononuclear cells by polymerase chain reaction amplification of bcl-2 translocations. J. Clin. Oncol. 12:1021, 1994.
28. Gribben, J.G., Saporito, L., Barber, M., et al. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction detectable lymphoma cells using monoclonal antibodies and immunogenic bead depletion. Blood 80:1083, 1992.